Tandem Diabetes Care (TNDM) Operating Income Growth (3y) (2016 - 2026)
Tandem Diabetes Care (TNDM) Operating Income Growth (3y) (2016 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn | -3.76% |
| 2 | Stryker | 128.82 Bn | 125.94 Bn | 3.81 Bn | 8.39% |
| 3 | Medtronic | 108.74 Bn | 99.52 Bn | 6.41 Bn | 6.17% |
| 4 | Boston Scientific | 68.40 Bn | 66.95 Bn | 3.61 Bn | 25.88% |
| 5 | Edwards Lifesciences | 47.42 Bn | 43.74 Bn | 1.29 Bn | 7.13% |
| 6 | GE HealthCare Technologies | 28.47 Bn | 26.18 Bn | 1.98 Bn | -2.70% |
| 7 | Dexcom | 28.42 Bn | 27.30 Bn | 750.30 Mn | 75.54% |
| 8 | Smith & Nephew | 26.97 Bn | 26.40 Bn | - | - |
| 9 | Koninklijke Philips | 25.52 Bn | 22.39 Bn | 2.07 Bn | 34.83% |
| 10 | Tandem Diabetes Care | 1.15 Bn | 577.45 Mn | 136.79 Mn | 48.52% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 48.52% |
| Dec 31, 2025 | 35.11% |
| Sep 30, 2025 | 21.63% |
| Jun 30, 2025 | -61.77% |
| Mar 31, 2025 | -99.00% |
| Dec 31, 2024 | -26.94% |
| Sep 30, 2024 | -75.22% |
| Jun 30, 2024 | -97.17% |
| Mar 31, 2024 | -134.38% |
| Dec 31, 2023 | -57.12% |
| Sep 30, 2023 | -215.03% |
| Jun 30, 2023 | -47.73% |
| Mar 31, 2023 | -111.17% |
| Dec 31, 2022 | -117.52% |
| Sep 30, 2022 | -99.25% |
| Jun 30, 2022 | -87.22% |
| Mar 31, 2022 | -11.73% |
| Dec 31, 2021 | 183.34% |
| Sep 30, 2021 | 35.57% |
| Jun 30, 2021 | 33.66% |